Cboe Canada Inc. has announced the listing of GuideAI Health Corp., an artificial intelligence healthcare company focused on improving the detection, management, and outcomes of vascular disease. The company's common shares are now available for trading on the exchange under the symbol GDAI. This listing provides investors access to shares through standard investment channels, including discount brokerages and full-service dealers, and offers the company a robust platform for capital formation and liquidity.

GuideAI is developing an AI platform designed to transform complex medical imaging and clinical data into actionable diagnostic insights. Its mission is to make advanced cardiovascular diagnostic intelligence accessible to a broader range of healthcare providers beyond major academic and research centers. The platform analyzes routine CT scans to identify peripheral vascular disease, aiming to improve patient outcomes while assisting hospitals and radiology groups in delivering comprehensive vascular care.

"Going public marks an important milestone for GuideAI as we scale our platform and broaden access to life-changing diagnostic technology," said Raj Shah, CEO of GuideAI Health Corp. He emphasized the company's commitment to delivering on its mission for patients, clinicians, and shareholders.

Cboe Canada CEO Joacim Wiklander welcomed the company, noting that its work at the intersection of artificial intelligence and cardiovascular health represents the kind of innovative, high-growth enterprise that Canadian public markets should support. The exchange provides deep expertise in emerging sectors and facilitates close to 15% of all trading volume in Canadian listed securities.

Key Listing Details

Cboe Canada lists companies and investment products seeking a robust and internationally recognized platform that enables investor trust, quality liquidity, and broad awareness. The forward-looking statements in the announcement are based on management's assumptions and are subject to risks, including potential changes in market conditions.

GuideAI Health Corp. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for VascularAssist Occlusion Triage (VAOT), an artificial intelligence software designed to support the prioritization and triage of vascular occlusion in the lower extremities. The clearance, granted on June 22, 2026, marks a significant step for the company in integrating AI into radiology workflows to improve patient outcomes for those at risk of limb-threatening disease.

VAOT is a Class II, AI-based Software as a Medical Device (SaMD) operating as a Computer-Aided Triage and Notification device (CADt). The software assists radiologists in identifying and characterizing significant peripheral vascular disease (PVD), a leading contributor to acute and chronic limb ischemia. By flagging suspected vascular occlusion for prioritized review within existing imaging workflows, VAOT aims to help clinical teams reduce time to diagnosis and intervention.

In clinical performance testing supporting the clearance, VAOT demonstrated strong accuracy in identifying disease at the patient level. The software achieved 95% patient-level sensitivity in 2D analysis and 94% patient-level sensitivity in 3D analysis for identifying Peripheral Artery Disease-positive patients, defined as patients with at least one lesion at 50% or greater stenosis.

"Receiving FDA 510(k) clearance for VAOT is a defining milestone for GuideAI and for the patients we ultimately aim to serve," said Raj Shah, MD, MBA, Chief Executive Officer of GuideAI Health. "Peripheral vascular disease is too often missed or detected late, with devastating consequences. VAOT brings AI-powered triage directly into the radiology workflow, helping clinicians identify vascular disease sooner so patients can be directed to the right care faster."

Clinical Performance Metrics

The following table summarizes the clinical performance metrics achieved by VAOT during testing:

GuideAI Health Corp. is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease and other vascular conditions that are frequently missed or under-reporting, generating structured, actionable reports for radiologists and treating clinicians.